NewAmsterdam Pharma Company NAMS Accrued Liabilities & Other
Accrued Liabilities & Other at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's accrued liabilities & other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's accrued liabilities & other?
- NewAmsterdam Pharma Company (NAMS) reported accrued liabilities & other of $5.09M in Q1 2026.
- How has NewAmsterdam Pharma Company's accrued liabilities & other changed year-over-year?
- NewAmsterdam Pharma Company's accrued liabilities & other decreased by 36.5% year-over-year, from $8.02M to $5.09M.
- What is the long-term trend for NewAmsterdam Pharma Company's accrued liabilities & other?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's accrued liabilities & other has grown at a 36.1% compound annual growth rate (CAGR), from $6.12M to $15.42M.
- What does accrued liabilities & other mean?
- Combined accrued expenses and miscellaneous current liabilities not classified in specific categories.